Neurosonix wins European cardiac surgery innovation award for ultrasound
device
4 October 2007 Neurosonix Ltd has received an award from the European
Association of Cardio-Thoracic Surgery (EACTS) for its EmBlocker ultrasound
device that provides protection against cerebral embolism during heart
surgery. The award honours technological breakthroughs in all areas
related to thoracic and cardiovascular research. “We are honoured that the
EACTS has acknowledged the breakthrough we achieved in offering the cardiac
surgeons and their patients a unique solution aimed at reducing the risk of
brain injury following cardiac surgery,” says Professor Simcha Milo,
inventor of the technology and co-founder of Israel-based Neurosonix. “We
are very excited that the EACTS recognized that the award-winning technology
of the EmBlocker has the potential to change standard cardiac surgery
practice.” Cerebral embolism is considered a major cause of brain injury
during cardiac surgical procedures. The EmBlocker, which is Neurosonix's
first device, uses proprietary ultrasound-based technology to non-invasively
divert emboli flow away from the cerebral arteries in order to reduce the
risk of post-operative brain injury. Prof. Jos Maessen, principal
investigator of the pilot clinical study, Head of the Cardio-Thoracic
Surgery Department at the Academic Hospital of Maastricht, the Netherlands,
officially presented the results of the study at the 2007 EACTS Meeting. The
study showed a significant decrease of over 65% of emboli flow to the brain
in patients treated with the EmBlocker.
“This is an important day for us, because the surgical community who faces
the devastating results of brain injury, acknowledged the importance of the
ground-breaking solution developed by Neurosonix,” says Dr Nathan Sela,
Neurosonix CEO.
Neurosonix expects to release the EmBlocker to the European market during
2008. To top
Save this page on del.icio.us
|